Originally published as JCO Early Release 10.1200/JCO.2008.16.5449 on September 22 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dudley, M. E. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Dudley, M. E. Articles by Rosenberg, S. A. Social Bookmarking                            What's this?

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Mark E. Dudley, James C. Yang, Richard Sherry, Marybeth S. Hughes, Richard Royal, Udai Kammula, Paul F. Robbins, JianPing Huang, Deborah E. Citrin, Susan F. Leitman, John Wunderlich, Nicholas P. Restifo, Armen Thomasian, Stephanie G. Downey, Franz O. Smith, Jacob Klapper, Kathleen Morton, Carolyn Laurencot, Donald E. White, Steven A. Rosenberg

From the Surgery Branch, Radiation Oncology Branch, National Cancer Institute; and the Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

Corresponding author: Mark E. Dudley, PhD, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC 3W-5752, 10 Center Drive, Bethesda, MD 20892-1201; e-mail: Mark_Dudley{at}nih.gov

Purpose The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective response rates of 12% to 15%. We previously reported that adoptive cell therapy (ACT) with autologous antitumor lymphocytes in lymphodepleted hosts mediated objective responses in 51% of 35 patients. Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens.

Patients and Methods We performed two additional sequential trials of ACT with autologous tumor-infiltrating lymphocytes (TIL) in patients with metastatic melanoma. Increasing intensity of host preparative lymphodepletion consisting of cyclophosphamide and fludarabine with either 2 (25 patients) or 12 Gy (25 patients) of total-body irradiation (TBI) was administered before cell transfer. Objective response rates by Response Evaluation Criteria in Solid Tumors (RECIST) and survival were evaluated. Immunologic correlates of effective treatment were studied.

Results Although nonmyeloablative chemotherapy alone showed an objective response rate of 49%, when 2 or 12 Gy of TBI was added, the response rates were 52% and 72% respectively. Responses were seen in all visceral sites including brain. There was one treatment-related death in the 93 patients. Host lymphodepletion was associated with increased serum levels of the lymphocyte homeostatic cytokines IL-7 and IL-15. Objective responses were correlated with the telomere length of the transferred cells.

Conclusion Host lymphodepletion followed by autologous TIL transfer and IL-2 results in objective response rates of 50% to 70% in patients with metastatic melanoma refractory to standard therapies.

published online ahead of print at www.jco.org on September 22, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information can be found for the following: NCT00335127 [ClinicalTrials.gov] , NCT00096382 [ClinicalTrials.gov] , NCT00019942 [ClinicalTrials.gov]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells Clin. Cancer Res., July 1, 2009; 15(13): 4499 - 4507. [Abstract] [Full Text] [PDF]

				R. Mortarini, C. Vegetti, A. Molla, F. Arienti, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, and A. Anichini Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage Clin. Cancer Res., June 15, 2009; 15(12): 4085 - 4094. [Abstract] [Full Text] [PDF]

				M. E. Dudley and S. A. Rosenberg Clinical Trials Investigating Adoptive Cell Therapy Combined with Lymphodepletion for Patients with Advanced Cancer ASCO Educational Book, January 1, 2009; 2009(1): 516 - 520. [Abstract] [Full Text] [PDF]

				A. Mackensen Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy ASCO Educational Book, January 1, 2009; 2009(1): 521 - 524. [Abstract] [Full Text] [PDF]